← Back to Search

Local Anesthetic

Guanfacine + Lidocaine for Trigeminal Neuralgia

Phase 2
Waitlist Available
Led By David Edwards
Research Sponsored by Vanderbilt University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if guanfacine can make lidocaine more effective in reducing facial pain for patients with trigeminal neuralgia by making the pain relief last longer. Guanfacine is primarily used for treating ADHD and has been found to help with symptoms in children.

Eligible Conditions
  • Trigeminal Neuralgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Time to Return to Baseline Pain After Injection.
Secondary study objectives
Frequency of acute trigeminal nerve pain attacks during follow-up
Pain intensity after treatment to be measured throughout follow-up
Quality of life after treatment
+2 more

Side effects data

From 2011 Phase 4 trial • 212 Patients • NCT00429273
36%
Decreased Appetite
34%
Insomnia
33%
Headache
26%
Irritability
23%
Abdominal Pain
23%
Sedation
23%
Lethargy
21%
Somnolence
17%
Fatigue
14%
Abdominal Pain Upper
11%
Affect Lability
10%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 1: Guan-Guan+Placebo
Group 2: Placebo-Placebo+DMPH
Group 3: Guan-Guan+DMPH

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Lidocaine then Lidocaine + GuanfacineExperimental Treatment2 Interventions
Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1). Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine.
Group II: Lidocaine + Guanfacine then LidocaineExperimental Treatment2 Interventions
Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1). Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Guanfacine
2008
Completed Phase 4
~2180
Lidocaine
2011
Completed Phase 4
~1370

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor
900 Previous Clinical Trials
939,469 Total Patients Enrolled
David EdwardsPrincipal Investigator - Vanderbilt University Medical Center
Centennial Medical Center-Women's Hospital, Sterling Primary Care, Sterling Primary Care Associates LLC, TriStar Centennial Medical Center, TriStar Parthenon Pavilion
University Of North Carolina At Chapel Hill School Of Medicine (Medical School)
Vanderbilt University Medical Center (Residency)
1 Previous Clinical Trials
625 Total Patients Enrolled
Tigran Kesayan, MDPrincipal InvestigatorVanderbilt University Medical Center

Media Library

Lidocaine (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT03865940 — Phase 2
Trigeminal Neuralgia Research Study Groups: Lidocaine + Guanfacine then Lidocaine, Lidocaine then Lidocaine + Guanfacine
Trigeminal Neuralgia Clinical Trial 2023: Lidocaine Highlights & Side Effects. Trial Name: NCT03865940 — Phase 2
Lidocaine (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03865940 — Phase 2
Trigeminal Neuralgia Patient Testimony for trial: Trial Name: NCT03865940 — Phase 2
~6 spots leftby Nov 2025